Releases Geral
EAACI Congress Kicks Off in Valencia, Spain
AGÊNCIA DE COMUNICAÇÃO Conteúdo de responsabilidade da empresa 31 de maio de 2024
European Academy of Allergy and Clinical Immunology
VALENCIA, Spain, May 31, 2024 (GLOBE NEWSWIRE) — The EAACI International Congress has commenced with the slogan Revolutionizing patient care through the power of data science. Over the next four days, experts will discuss the latest advancements in this impactful area. Allergies, which represent a significant public health issue, encompass a variety of conditions.
Drug allergy is a major adverse reaction that can have serious consequences. Antibiotics, particularly penicillin and its derivatives, are the drugs that most frequently cause allergic reactions, says Maria Jose Torres, Secretary General of EAACI. NSAIDs, radiological contrast media, and chemotherapeutics are also responsible for a significant proportion of reactions, she details.
Asthma, especially when combined with obesity, has a considerable impact on quality of life if not properly managed. These two prevalent health conditions significantly affect people’s quality of life, stresses André Moreira, Co-Chair of the Congress Scientific Program.
Another major topic is the progress made in the treatment of allergies. As Stefano Del Giacco, President of EAACI, explains, In the field of precision medicine, identifying genetic variants associated with increased susceptibility to allergies and using specific biomarkers have improved the management of some types of allergies, allowing the development of more personalised treatments.
We are achieving excellent results in the application of immunotherapy for allergic rhinitis and asthma, says Mübeccel Akdis, Co-Chair of the Congress Scientific Program. This also applies to food allergies, with oral therapy or the personalisation of vaccines based on the patient’s immunological profile.
Big Data in Allergology enables the collection and analysis of large amounts of clinical, genetic, and environmental data, which are used to identify risk factors and allergy patterns, notes Mohamed Shamji, Vice President of the EAACI Congress. AI enhances allergy diagnosis through advanced analysis of clinical data and plays a crucial role in developing new treatments by identifying therapeutic targets and optimizing molecules. We are at a time of great and promising advances, though not without challenges, concludes Shamji.
Press Contact EAACI
+41 44 205 55 33
communications@eaaci.org
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a7b50aa2-2473-4832-9ed0-73a70d86d865
A OESP nao e(sao) responsavel(is) por erros, incorrecoes, atrasos ou quaisquer decisoes tomadas por seus clientes com base nos Conteudos ora disponibilizados, bem como tais Conteudos nao representam a opiniao da OESP e sao de inteira responsabilidade da GlobeNewswire
Leia também
-
Releases Geral Omnichannel impulsiona empresas B2B em 10%, aponta pesquisa
1 de dezembro de 2023DINO DIVULGADOR DE NOTÍCIAS (DINO – 01 dez, 2023) – A B2B Pulse, pesquisa realizada pela consultoria empresarial americana McKinsey & Company, apontou que empresas B2B
Saiba Mais -
Releases Geral Vendas de Páscoa podem gerar aumento de 2% no faturamento do comércio, segundo ACSP
25 de março de 2024São Paulo, 25 de março de 2024. A Associação Comercial de São Paulo (ACSP) avalia que as vendas de Páscoa poderão registrar
Saiba Mais -
Releases Geral Franquia de fast food seleciona master franqueados no Brasil
20 de fevereiro de 2024DINO DIVULGADOR DE NOTÍCIAS São Paulo, SP–(DINO – 20 fev, 2024) – Em 2023, o mercado de franquias no Brasil experimentou um crescimento robusto de 13,8%, atingindo uma receita de
Saiba Mais